Capital Investment Counsel Inc’s Heron Therapeutics HRTX Stock Holding History

Capital Investment Counsel Inc’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.82K	Hold	18,325	–	–	﹤0.01%	257
2026 Q1	$14.7K	Hold	18,325	–	–	﹤0.01%	246
2025 Q4	$23.8K	Buy	+18,325	New	+$22.6K	﹤0.01%	242
2025 Q3	–	Sell	-14,625	Closed	-$30.3K	–	212
2025 Q2	$30.3K	Hold	14,625	–	–	﹤0.01%	231
2025 Q1	$32.2K	Hold	14,625	–	–	﹤0.01%	221
2024 Q4	$22.4K	Hold	14,625	–	–	﹤0.01%	232
2024 Q3	$29.1K	Hold	14,625	–	–	﹤0.01%	206
2024 Q2	$51.2K	Buy	14,625 +3,125	+27%	+$9.6K	0.01%	197
2024 Q1	$31.9K	Hold	11,500	–	–	0.01%	205
2023 Q4	$19.6K	Buy	+11,500	New	+$12.7K	﹤0.01%	209

Other funds holding HRTX

CPC

Congress Park Capital Saratoga Springs, New York $370M AUM 26.01% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

CWP

Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return

Apeiron RIA Dallas, Texas $390M AUM 22.97% 1-Year Est. Return

AHL

Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return

DIM

DLK Investment Management Solana Beach, California $235M AUM 12.41% 1-Year Est. Return

Searle & Co Greenwich, Connecticut $445M AUM 41.72% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

CPIG

Chicago Partners Investment Group Chicago, Illinois $5B AUM 26.84% 1-Year Est. Return

Capital Investment Counsel Inc's HRTX Position: Q2 2026 in Review

Capital Investment Counsel Inc held its Heron Therapeutics (HRTX) position steady in Q2 2026 at 18,325 shares worth $7.82K. The position accounts for ﹤0.01% of the portfolio, ranked #257.

Capital Investment Counsel Inc first reported a position in HRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $51.2K in Q2 2024. 38 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

Capital Investment Counsel Inc held 18,325 shares of Heron Therapeutics worth $7.82K as of Q2 2026.
Capital Investment Counsel Inc left its Heron Therapeutics share count unchanged in Q2 2026.
Heron Therapeutics made up ﹤0.01% of Capital Investment Counsel Inc's portfolio in Q2 2026, its #257 holding.
Capital Investment Counsel Inc first reported a position in Heron Therapeutics in Q4 2023 and has held it in 10 quarters since.
Capital Investment Counsel Inc's Heron Therapeutics position peaked at $51.2K in Q2 2024.
38 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Capital Investment Counsel Inc's 13F filing for Q2 2026, filed 27 Jul 2026.